Showing results (81-90 of 108) with videos related to

Sort By:
Pageof 11
Oncoimmunology|March 26, 2013
Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylatePatricia Pautier, Clara Locher, Caroline Robert, et al.
Annals of Surgery|January 14, 2012
Hyperthermic pelvic perfusion with tumor necrosis factor-α for locally advanced cancers: encouraging results of a phase II studySylvie Bonvalot, Thierry de Baere, Jean Mendiboure, et al.
Journal of Medicinal Chemistry|December 16, 2014
Preactivated oxazaphosphorines designed for isophosphoramide mustard delivery as bulk form or nanoassemblies: synthesis and proof of conceptCharles Skarbek, Lea L Lesueur, Hubert Chapuis, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 14, 2008
Squalenoylation favorably modifies the in vivo pharmacokinetics and biodistribution of gemcitabine in miceL Harivardhan Reddy, Hania Khoury, Angelo Paci, et al.
Oncoimmunology|March 26, 2013
Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR+ NK cell levels correlate with disease outcomeNathalie Chaput, Caroline Flament, Clara Locher, et al.
European Journal of Cancer (Oxford, England : 1990)|May 29, 2012
Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: good tolerance profile and efficacy in rhabdomyosarcoma--a report from the Société Française des Cancers et leucémies de l'Enfant et de l'adolescent (SFCE)Véronique Minard-Colin, Jean-Laurent Ichante, Laurent Nguyen, et al.
International Journal of Pharmaceutics|May 21, 2011
A new nanomedicine based on didanosine glycerolipidic prodrug enhances the long term accumulation of drug in a HIV sanctuaryRym Skanji, Karine Andrieux, Muriel Lalanne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2017
Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter StudySotheara Moeung, Christine Chevreau, Sophie Broutin, et al.
Ejhaem|December 18, 2024
Incidence and risk factors of graft failure in allogeneic hematopoietic stem cell transplantation for mucopolysaccharidosis in a nationwide pediatric cohort. A study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular TherapyLaura Danhardt, Arnaud Wiedemann, Gerard Michel, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 3, 2016
Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines CommitteeJeanne Palmer, Jeannine S McCune, Miguel-Angel Perales, et al.
Pageof 11